Evidence map›Paper›PMID 39256648›Full record

ArticleBMC neurology2024

Neurological hospitalisations in childhood cancer survivors treated before 2001: findings from the French Childhood Cancer Survivor Study cohort.

David Rajaonera, Daniel Bejarano-Quisoboni, Jacques Grill, Rodrigue S Allodji, Nathalie Pelletier-Fleury, Neige Journy, Marjorie Boussac, François Doz, Giao Vu-Bezin, Monia Zidane and 9 more

Abstract read
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

David RajaoneraRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Daniel Bejarano-QuisoboniRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Jacques GrillDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Rodrigue S AllodjiRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Nathalie Pelletier-FleuryUniversité Paris-Saclay, Paris, France.
Neige JournyRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Marjorie BoussacFrench National Health Insurance (CNAM), Paris, France.
François DozSIREDO centre (Care, Innovation, Research in Pediatric, Adolescent and Young Adults Oncology), Institut Curie and University Paris Cité, Paris, France.
Giao Vu-BezinRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Monia ZidaneRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Boris SchwartzRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Nadia HaddyRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Stéphanie BolleUniversité Paris-Saclay, Paris, France.
Chiraz El-FayechDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Christelle DufourDepartment of Children and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Ibrahima DialloRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Gudrun SchleiermacherSIREDO centre and INSERM U830, Institut Curie, Paris, France.
Brice FresneauRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France.
Florent de VathaireRadiation Epidemiology Team, CESP, Inserm U1018, Villejuif, France. florent.devathaire@gustaveroussy.fr.

Funding

Institut National Du Cancer INCA RISP-SHS 2022
6 · The paper itself

Abstract

purposeChildhood cancer survivors (CCS) have an increased risk of developing late chronic diseases, which can be influenced by the cancer type and its treatment. These chronic diseases can be severe and disabling, typically emerging years to decades after treatment. These deficits negatively impact quality of life, intelligence quotient, and memory. This study investigated how much the cancer type and treatment could affect the neurological hospitalisations in the French Childhood Cancer Survivors Study (FCCSS).

methodsWe included 5579 childhood cancer survivors (CCS), diagnosed with solid tumours or lymphoma between 1945 and 2000, treated before 2001 and below the age of 21 years at initial treatment. The follow-up period was from 2006 to 2018. Hospitalisation data were obtained by linkage with the National Health Data System. We calculated the relative hospitalisation rate (RHRs) and absolute excess rate (AERs). Multivariable analyses were conducted using a Generalized Linear Model (GLM) with a Poisson distribution to estimate the association between neurological hospitalisation and patient characteristics. The expected number of hospitalisations served as an offset to compare the risk for FCCSS survivors with that of the reference population. Risk estimates were reported as relative risk (RR) with 95% confidence intervals.

resultsThe hospitalisation rate for CCS was 114.2 per 10,000 person-years (PY), compared to 48.4 in the reference population. The highest hospitalisation rates were observed for epilepsy (AER = 27.1 per 10000 PY, 95%CI: 23.5-31.2 and RHR = 5.1, 95%CI 4.4-5.7). In multivariable analyses, central nervous system (CNS) tumours survivors had the highest relative risk (RR) of hospitalisation (RR = 9.4, 95%CI: 6.7-13.1) followed by neuroblastoma survivors (RR = 2.5, 95%CI: 1.7-3.7). In the whole population, survivors who received radiation to the head and neck had a significantly higher risk of hospitalisation (RR = 3.9, 95%CI: 3.3-4.7) compared to those who did not receive radiotherapy.

conclusionsHead and neck irradiation was identified as a strong risk factor for hospitalisation. This underlines the importance of implementing specific neurologic surveillance programs for at-risk individuals.

Indexed as

Cancer SurvivorsHospitalizationNeoplasmsAdolescentAdultChildChild, PreschoolCohort StudiesFemaleFranceHumansInfantMaleNervous System DiseasesYoung AdultChildhood cancer survivorHospitalisationsNeurological diseasesRisk factor

Identifiers

PMID39256648
PMCPMC11386314

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.